Latest News of GLP
Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In.
Senator Bernie Sanders is summoning the CEO of Danish pharma company Novo Nordisk to a Senate committee to investigate high drug prices. This hearing will shed light on the practices of all big pharma...
Does 'nature's Ozempic' really work? Trendy GLP-1 supplements...
Store-bought supplements are claiming to offer similar weight loss benefits as prescription injections like Ozempic, at a fraction of the cost. However, doctors are skeptical about their effectiveness...
The best biotech plays outside the GLP-1 weight-loss market
BMO Capital Markets' Evan Seigerman discusses the booming biotech sector, highlighting GLP-1 weight-loss drugs' demand. He also points out opportunities in companies like Regeneron and Vertex, emphasi...
-
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
By Yahoo! Finance | 1 week agoGoldman Sachs predicts the anti-obesity market to reach $100 billion by 2030. Terns Pharmaceuticals may be a strong contender with its promising GLP-1 weight-loss pill. However, investors should be ca...
-
A woman lost 190 pounds from exercise, food journaling, and GLP-1 medication. She's now training for a marathon.
By Business Insider | 1 week agoA woman lost 190 lbs through walking, running, and dietary changes. She started by walking daily, then transitioned to running a mile daily. Her perseverance led her to complete a half-marathon and sh...
-
Gaming and Leisure Properties, Inc. (GLPI): A Best Casino Stock that Pay Dividends?
By Yahoo! Finance | 2 weeks agoGaming and Leisure Properties, Inc. (NASDAQ:GLPI) is a top casino stock that pays dividends, ranking 6th on the list. The company showed revenue growth and consistent dividend payouts, making it a str...
-
Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
By CNBC | 2 weeks agoDigital health company Noom introduces a new weight loss product featuring a compounded GLP-1 drug, offering an alternative to expensive branded medications. The program includes personalized support ...
-
Obesity drugs in kindergarten? A GLP-1 drug works for young kids, study finds.
By MarketWatch | 2 weeks agoResearchers suggest that Liraglutide, a GLP-1 medication by Novo Nordisk, can be safe and effective for children as young as 6 struggling with excess weight. A study found it reduced BMI by 5....
-
50 Million Eligible For GLP-1 Drug Coverage. And that's Just Those Under 65
By Forbes | 3 weeks agoA new analysis by KFF reveals that 42% of U.S. adults with private insurance under 65 may be eligible for GLP-1 drugs for conditions like type 2 diabetes and obesity. This could impact employer health...
-
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
By Yahoo! Finance | 3 weeks agoVivani Medical's GLP-1 implant shows promising results in reducing liver fat in obese mice, supporting its potential for weight loss and metabolic disorder treatment. The company's first clinical stud...
-
Beyond The Sticker Shock: Why GLP-1s Might Save More Than They Cost
By Forbes | 3 weeks agoGLP-1s are rising in popularity in the U.S., used for diabetes and weight loss. Despite high costs, they address major health issues like diabetes and obesity, potentially reducing overall healthcare ...
-
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
By Yahoo! Finance | 1 month agoNovo Nordisk's drugs like Ozempic and Wegovy have been successful in treating obesity and type 2 diabetes. Biotechs like Zealand Pharma are developing new GLP-1 drugs that may rival existing options....
-
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
By Yahoo! Finance | 1 month agoThe anti-obesity drug market holds a potential value of $100 billion, with Eli Lilly and Novo Nordisk being key players. Their GLP-1 drugs show promise, with Eli Lilly's products potentially surpassin...
-
GLP-1s partly to blame for spike in health insurance costs in 2025
By Yahoo! Finance | 1 month agoEmployer healthcare costs may rise by 8-9% due to increased GLP-1 use, costing workers up to 20% of their premiums. GLP-1 costs have surged, contributing to a significant portion of spending increases...
-
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
By Yahoo! Finance | 1 month agoNovo Nordisk and Eli Lilly lead the weight loss market with GLP-1 drugs, but face competition from Roche. Roche's upcoming GLP-1 weight loss drugs show promise, potentially challenging the market lead...